Addex Therapeutics Ltd
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Timothy Mark Dyer
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Chemin des Mines, 9 Geneva Switzerland 1202
- IPO Date
- Feb 12, 2020
- CIK
- 0001574232
- Website
- addextherapeutics.com
- Similar Companies
- Business
- Addex Therapeutics Ltd Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule allosteric modulators targeting neurological disorders; its lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for brain injury recovery including post-stroke and traumatic brain injury recovery as well as Parkinson's disease levodopa-induced dyskinesia; ADX71149 (mGlu2 positive allosteric modulator or PAM) is a Phase 2 asset for epilepsy, schizophrenia and anxious depression; the company advances GABAB PAM programs for chronic cough and substance use disorders; preclinical candidates include mGlu7 NAM for post-traumatic stress disorder and mood disorders, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease, mGlu3 PAM for neurodegenerative disorders and GABAB PAM for pain and overactive bladder; it holds a 20% equity interest in Neurosterix LLC, a spin-out advancing additional allosteric modulators such as M4 PAM for schizophrenia. Addex Therapeutics Ltd , founded in 2002 and headquartered in Geneva, Switzerland, operates primarily in Europe with shares listed on the SIX Swiss Exchange and American Depositary Shares on NASDAQ Capital Market under the ticker ADXN. Recent developments include regaining rights to the Phase 2 mGlu2 PAM asset ADX71149 previously partnered with Janssen Pharmaceuticals Inc.; entering an option agreement with Sinntaxis for exclusive intellectual property rights covering mGlu5 NAM use in brain injury recovery; advancing its independent GABAB PAM program for chronic cough with robust preclinical anti-tussive data presented in 2025; partner Indivior successfully completing IND-enabling studies for its GABAB PAM candidate in substance use disorders; spinning out Neurosterix LLC in 2024 receiving CHF5 million and 20% equity; and leading a financing in Stalicla for precision medicine in neurodevelopmental disorders.
Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Drops By 38.2%
Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Expands By 137.6%
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
Critical Analysis: Addex Therapeutics (NASDAQ:ADXN) & Aditxt (NASDAQ:ADTX)
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
Addex Appoints Bank of New York Mellon as Depositary Bank
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
Addex Shareholders Approve All Resolutions at Annual General Meeting
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update